Form 8-K - Current report:
SEC Accession No. 0001404644-25-000044
Filing Date
2025-05-09
Accepted
2025-05-09 07:30:59
Documents
17
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20250509.htm   iXBRL 8-K 26985
2 EX-99.1 ngne_1q2025release.htm EX-99.1 24714
6 image_0.jpg GRAPHIC 3474
7 image_1.jpg GRAPHIC 700575
8 image_2.jpg GRAPHIC 794808
  Complete submission text file 0001404644-25-000044.txt   2248632

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20250509.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20250509_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20250509_pre.xml EX-101.PRE 13050
19 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20250509_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 25928388
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)